Exact Mass: 628.3584298000001

Exact Mass Matches: 628.3584298000001

Found 230 metabolites which its exact mass value is equals to given mass value 628.3584298000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lopinavir

N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide

C37H48N4O5 (628.3624517999999)


Lopinavir is only found in individuals that have used or taken this drug. It is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles. D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2288 Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

BQ 485

N-(N-(N-((Hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-D-tryptophan

C35H44N6O5 (628.3373014)


   

(3S,5R,6R,6'S)-6,7-Didehydro-5,6-dihydro-3,5,6'-trihydroxy-13,14,20-trinor-3'-oxo-beta,epsilon-caroten-19',11'-olide 3-acetate

3-Hydroxy-4-[(3E,5E,7E,9E)-10-{[(2Z)-4-[(e)-2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxo-2,5-dihydrofuran-2-ylidene]methyl}-3-methylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetic acid

C39H48O7 (628.3399858)


(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is found in mollusks. (3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is a constituent of the oyster Crassostrea gigas. Constituent of the oyster Crassostrea gigas. (3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is found in mollusks.

   

LysoPI(20:0/0:0)

[(2R)-2-hydroxy-3-(icosanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C29H57O12P (628.3587451999999)


LysoPI(20:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(20:0/0:0), in particular, consists of one chain of arachidic acid at the C-1 position.

   

N-(N-(N-((Hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-D-tryptophan

2-({2-[(2-{[(azepan-1-yl)(hydroxy)methylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene}amino)-3-(1H-indol-3-yl)propanoate

C35H44N6O5 (628.3373014)


   

Cholylglycyltyrosine

3-(4-hydroxyphenyl)-2-[2-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)acetamido]propanoic acid

C35H52N2O8 (628.3723472)


   

Plactin D

N-{3-[14-benzyl-8,11-bis(2-methylpropyl)-3,6,9,12,15-pentaoxo-5-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]propyl}guanidine

C32H52N8O5 (628.4060462)


   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(decanoyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

[(2R)-2-(decanoyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-3-(decanoyloxy)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-3-(decanoyloxy)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-3-(decanoyloxy)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   

2-N-(1-Deoxy-1-beta-D-fructopyranosyl)cephaeline

2-N-(1-Deoxy-1-beta-D-fructopyranosyl)cephaeline

C34H48N2O9 (628.3359638)


   

2-N-(1-deoxy-1-beta-D-fructopyranosyl)neocephaeline

2-N-(1-deoxy-1-beta-D-fructopyranosyl)neocephaeline

C34H48N2O9 (628.3359638)


   
   
   

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

onchitriol II D|Onchitriol IID

onchitriol II D|Onchitriol IID

C36H52O9 (628.3611142)


   

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

C32H52O12 (628.3458592)


   

Me ester,Tri-Ac-(2alpha,3beta)-2,3,30-Trihydroxy-12-oleanen-28-oic acid

Me ester,Tri-Ac-(2alpha,3beta)-2,3,30-Trihydroxy-12-oleanen-28-oic acid

C37H56O8 (628.3974976000001)


   

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

C40H44N4O3 (628.3413234)


   

milbemycins VM48641

milbemycins VM48641

C36H52O9 (628.3611142)


   
   

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

C36H52O9 (628.3611142)


   

De-O-methyltenuicausine

De-O-methyltenuicausine

C40H44N4O3 (628.3413234)


   
   
   

11-(3-methylbutanoyl)ilikonapyrone

11-(3-methylbutanoyl)ilikonapyrone

C37H56O8 (628.3974976000001)


   

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

C33H56O11 (628.3822426)


   
   
   
   
   
   

onchitriol I A|Onchitriol IA

onchitriol I A|Onchitriol IA

C36H52O9 (628.3611142)


   
   

Phorbol-12-tiglate-13-laurate

Phorbol-12-tiglate-13-laurate

C37H56O8 (628.3974976000001)


   

Integracin A

Integracin A

C37H56O8 (628.3974976000001)


A benzoate ester obtained by the formal condensation of the hydroxy group of 5-(8-hydroxyundecyl)benzene-1,3-diol with 4,6-dihydroxy benzoic acid which is also substituted by a 8-(acetoxy)undecyl group at position 2. It is isolated from Cytonaema sp. and has anti-HIV-1 activity.

   

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

C33H56O11 (628.3822426)


   
   

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

C40H52O6 (628.3763692)


   
   
   
   

Lopinavir

Lopinavir (ABT-378)

C37H48N4O5 (628.3624517999999)


D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Lys Arg Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Lys Tyr Arg Tyr

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Lys Tyr Tyr Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]pentanoic acid

C30H44N8O7 (628.3332794)


   

Arg Lys Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Arg Tyr Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Arg Tyr Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Lys Arg Tyr

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Lys Tyr Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Arg Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Arg Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Tyr Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-5-carbamimidamidopentanoic acid

C30H44N8O7 (628.3332794)


   

Tyr Tyr Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]hexanoic acid

C30H44N8O7 (628.3332794)


   

RLLNN

Arg-Leu-Leu-Asn-Asn

C26H48N10O8 (628.3656408)


   

PI(20:0/0:0)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   

(3S,5R,6R,6'S)-6,7-Didehydro-5,6-dihydro-3,5,6'-trihydroxy-13,14,20-trinor-3'-oxo-beta,epsilon-caroten-19',11'-olide 3-acetate

3-hydroxy-4-[(3E,5E,7E,9E)-11-[(2Z)-4-[(E)-2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxo-2,5-dihydrofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C39H48O7 (628.3399858)


   
   

LPI 20:0

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   

Astaxanthin-5,6-peroxide

5,6-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

Astaxanthin-5,8-peroxide

5,8-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

2,2-Dihydroxyastaxanthin

(2R,3S,2R,3S)-2,3,2,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

(3S,5R,6S)-3-ethanoyloxy-5,6-dihydroxy-5,67,8-tetradehydro-11,19-olide-20-nor-beta,epsilon-caroten-3-one

(3S,5R,6S)-3-ethanoyloxy-5,6-dihydroxy-5,67,8-tetradehydro-11,19-olide-20-nor-beta,epsilon-caroten-3-one

C39H48O7 (628.3399858)


   

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

C29H52N6O9 (628.3795582)


   

Levalbuterol tartrate

Levalbuterol tartrate

C30H48N2O12 (628.3207087999999)


C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   

Cholylglycyltyrosine

Cholylglycyltyrosine

C35H52N2O8 (628.3723472)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

cyclo[DL-Arg-DL-Val-DL-Leu-DL-Leu-DL-Phe]

cyclo[DL-Arg-DL-Val-DL-Leu-DL-Leu-DL-Phe]

C32H52N8O5 (628.4060462)


   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

C33H57O9P (628.3740002)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C33H57O9P (628.3740002)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C33H57O9P (628.3740002)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

C33H57O9P (628.3740002)


   
   

Perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp

Perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp

C35H44N6O5 (628.3373014)


   

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

C33H48N4O8 (628.3471968)


   

Dabigatran etexilate cation

Dabigatran etexilate cation

C34H42N7O5+ (628.3247262)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3624517999999)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3624517999999)


   
   

3-Didehydro-5-dehydroxyhydratoperidinin

3-Didehydro-5-dehydroxyhydratoperidinin

C39H48O7 (628.3399858)


   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

C29H57O12P (628.3587451999999)


   
   
   
   
   
   
   
   
   
   
   
   

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C29H57O12P (628.3587451999999)


   

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C32H53O10P (628.3376168)


   

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C32H53O10P (628.3376168)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C32H53O10P (628.3376168)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] hexadecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] hexadecanoate

C28H53O13P (628.3223618)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C32H53O10P (628.3376168)


   

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tridecanoate

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tridecanoate

C28H53O13P (628.3223618)


   

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

C28H53O13P (628.3223618)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] decanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] decanoate

C28H53O13P (628.3223618)


   

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C32H53O10P (628.3376168)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetradecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetradecanoate

C28H53O13P (628.3223618)


   

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

C28H53O13P (628.3223618)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] undecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] undecanoate

C28H53O13P (628.3223618)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C32H53O10P (628.3376168)


   

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

C28H53O13P (628.3223618)


   

[(1R,3S)-3-hydroxy-4-[(3E,5E,7E,9E,11Z)-11-[4-[(E)-2-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate

[(1R,3S)-3-hydroxy-4-[(3E,5E,7E,9E,11Z)-11-[4-[(E)-2-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate

C39H48O7 (628.3399858)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C35H49O8P (628.3164884)


   

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C32H53O10P (628.3376168)


   

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C32H53O10P (628.3376168)


   

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C32H53O10P (628.3376168)


   

2-[[3-heptanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-heptanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[hydroxy-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

C40H44N4O3 (628.3413234)


   

(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate

(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate

C39H48O7 (628.3399858)


   

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247308)


   

2-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

2-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.3399858)


   

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611142)


   

(2s,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

(2s,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

C34H48N2O9 (628.3359638)


   

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

C34H48N2O9 (628.3359638)


   

methyl (4as,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4as,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3458592)


   

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611142)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247308)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611142)


   

methyl (4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

n-{2-[({11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methoxy)carbonyl]phenyl}ethanimidic acid

n-{2-[({11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methoxy)carbonyl]phenyl}ethanimidic acid

C34H48N2O9 (628.3359638)


   

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247308)